Category Archives: Cancer Research

Mikhail Blagosklonny Uses Experience to Help Cancer Patients

Mikhail Blagosklonny’s entire career has been about cancer patients and what he can do to help them. Since he is an oncologist, he has seen a lot of cancer patients and has learned a lot about the things that they are going through. He knows that there are some major problems with the way that cancer treatment works and that most people suffer from poor immune systems as a result of the cancer treatment that they are getting. For all of these reasons, Mikhail Blagosklonny did what he could to make sure that people had the help that they needed when undergoing treatment and it is what made things even better for people.Since Mikhail Blagosklonny started Oncotarget, even more people have learned about the cancer treatment options that they have. One of the most important things for people to realize about Oncotarget is that it is a peer review publication. It is not intended to directly help patients, but it can be used by oncologists who want to provide even more help to all of their patients. In this way, it is making a difference in cancer treatment and is making things better for even more people to try different things.

Doctors who use Oncotarget know that they will be able to make things easier on people who are undergoing treatment. They can learn about the things that can be used in the industry and they know that their field is important to cancer treatment. Doctors also know that they have to make all of the right choices with Oncotarget if they want to be able to help their patients out in a way that will truly give them everything that they need so that they can enjoy different things that they can do with their own lives.Patients can even benefit from the things that doctors who are not oncologists can contribute to Oncotarget. Mikhail Blagosklonny made the publication so that more than just oncologists would be able to contribute. It made things easier for people to realize what was going on and made it easier for doctors to have a positive influence on the people who were trying to fix their patients.

They wanted to be able to show more people what they could do with the issues that they had and with the experiences that they had on their own in different areas of the cancer treatment section.Despite all of the issues that come along with cancer, some doctors do what they can to help treat these issues. Recently, Mikhail Blagosklonny found out about anti-aging treatments. He realized that he could use these for people who had immune system issues as a result of cancer. This is what would help them to be healthier and would allow them to feel better while getting treatment. He would not have found out about this type of treatment if it weren’t for the fact that he used Oncotarget to show people what they could get out of these types of situations.


Benefits Of Oncotarget To Researchers

Oncotarget began as an online platform where scientists could post and access latest papers or publications on oncology. It became very successful over time that the editors introduced new branches such as microbiology, neuroscience, aging, immunology, pathology, autophagy, and cell death. However, Oncotarget’s primary focus is still oncology.

The impact brought about by Oncotarget is quite fascinating. Unlike before, now researchers can share their work as soon as they complete them. They no longer have to wait for reviews to so as to make their work available to the rest of the world.

Read more:

The editors on this online platform ensure the site is up and running always, enabling their target audience to post and access updates on a weekly basis. Researchers can also post unfinished works here and be able to read all the unbiased reviews made by other scientists. Most times, these researchers use the comments made to better their research and even complete and present their papers for publication.

Medicine students also benefit immensely from Oncotarget. They can find most, if not all, of the materials they require for their projects here. It, therefore, means that they do not have to spend a lot of time completing their work or even include outdated research in their projects since they have access to updated publications.

If you are a new researcher, you need not worry about rejection of your papers. Oncotarget is known to have a very high acceptance rate of work that is outstanding and of great impact. Just make sure your research is extensive and up to date.

According to this article, Oncotarget charges researchers a nominal fee for the publication, promotion or archiving of their work. The amount is negotiable. Hence, scientists are allowed to ask for a discount before submitting their papers. However, news or editorials of 800 words or less are free.

Oncotarget’s mission is to make scientific results widely and rapidly available to everyone across the globe. It links different scientific fields in medicine thus eliminating the border between specialties.

Oncotarget has already hastened the rate at which science is expanding, and humanity can have faith that most of the diseases we know right now will go extinct pretty soon. Follow Oncotarget journal on Twitter.

An Overview of Oncologist Mikhail Blagosklonny’s Life and Career

Mikhail Blagosklonny is a renowned author of more than 260 articles published in various peer-reviewed journals. These papers have received more than 25,000 citations, which has made him attain an h-index of 83. Dr. Blagosklonny is the current associate editor of Cancer Biology Therapy and Cell Death Differentiation. He has also served on the editorial board of Autophagy, Cancer Research, PLOS ONE, Intenational J Cancer and the founding and current Cell Cycle editor-in-chief. His areas of interest in research range from cellular and molecular biology to medical investigations that include cell cycle, signal transduction, anticancer therapeutics, cellular senescence and fresh anticancer strategies. He increased his studies on signal transduction from cancer to the area of aging On This revealed potential targets useful for slowing down age-related diseases and aging.

Education and Career

He started off his career as an associate professor of medicine after getting appointed at the New York Medical College, Valhalla in 2002. He then became a senior scientist at at the Ordway Research Institute in Albany, New York. He held onto this position until 2009 when Blagosklonny was appointed as the Professor of Oncology, Roswell Park Cancer Institute.

Aging and the use of Rapamycin

Blagosklonny has come up with a hypothesis looking at the probable role of TOR signaling in cancer and aging. He proposes the use of rapamycin, which is a popular drug used for cancer as a potential treatment for extension of life. Rapamycin when administered in rational schedules and doses can prevent nephropathy, retinopathy and beta-cell failure without any side effects. Dr. Blagosklonny is known and considered as one of rapamycin’s passionate advocates in the longevity research.

Role at Roswell Park Cancer Institute

According to the Senior Vice-President at Roswell Park’s Basic Science and Chairman of Department of the Cell Stress Biology at, Andrei V. Gudkov, Mikhail is a pre-eminent researcher. Andrei praised his unique concepts that he has developed in cancer therapy and biology at the time when Dr. Blagosklonny was recruited at Roswell Park (April 15, 2009). Dr. Blagosklonny has helped in facilitating the development of fresh anti-cancer methods and strategies and various cancer prevention and therapy methods. He has been able to achieve all the above due to his approaches and ideas that include protecting normal body cells from chemo- and radiotherapy, tissue-specific and anti-tissue therapy, anticancer drugs selective combination and the slowdown of cancer via slowing down the aging process in organisms.